Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | TRPC6 | Q9Y210 | 7/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.40 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29637494 | 1.00 | NOS3 (0.44) | NOS3NOS1NOS2ALDH1A1PIK3CA | |
| SCHEMBL29637497 | 1.00 | NOS3 (0.44) | NOS3NOS1NOS2ALDH1A1PIK3CA | |
| SCHEMBL23068062 | 0.85 | P2RX3 (0.43) | NOS3NOS1NOS2PIK3CAMTOR | |
| SCHEMBL91466 | 0.82 | NOS3 (0.58) | NOS3NOS1NOS2ALDH1A1PIK3CA | |
| SCHEMBL21241205 | 0.82 | NOS3 (0.58) | NOS3NOS1NOS2ALDH1A1PIK3CA | |
| SCHEMBL22502131 | 0.81 | MCHR1 (0.44) | — | |
| SCHEMBL29637517 | 0.80 | DYRK1A (0.53) | NOS3NOS1NOS2ALDH1A1PIK3CA | |
| SCHEMBL10200683 | 0.80 | P2RX3 (0.40) | NOS3NOS1NOS2PIK3CAMTOR | |
| SCHEMBL2117006 | 0.80 | ALOX5AP (0.42) | NOS3NOS1NOS2ALDH1A1PIK3CA | |
| SCHEMBL29214455 | 0.80 | NOS3 (0.44) | NOS3NOS1NOS2PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615839-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20240199611-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2024-06-20 | — | — | US | disclosed |
| US-20240180886-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2024102794-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-16 | — | — | WO | disclosed |
| CN-113166156-B | Tyrosine kinase inhibitors, compositions and methods | 贝达药业股份有限公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-4028399-B1 | ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2024-02-14 | — | — | EP | disclosed |
| EP-4308239-A1 | ANTIBACTERIAL COMPOUNDS | Janssen Sciences Ireland Unlimited Company (IE) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396475-A | Antibacterial compounds | 爱尔兰詹森科学公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-111615388-B | Immunotherapeutic agent for cancer | 斯汀格瑞治疗股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11731960-B2 | Biheterocyclic compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-22 | — | — | US | disclosed |
| WO-2017122722-A1 | BIHETEROCYCLIC COMPOUND | 大日本住友製薬株式会社 | 2017-07-20 | — | — | WO | disclosed |
| CN-106458812-A | Compound containing modified phenolic hydroxy group, method for producing compound containing modified phenolic hydroxy group, photosensitive composition, resist material, and resist coating film | DIC株式会社 | 2017-02-22 | — | — | CN | disclosed |
| CN-103380130-B | Novel pyrazole and imidazole derivatives useful as orexin antagonists | ACTELION PHARMACEUTICALS LTD | 2015-06-17 | — | — | CN | disclosed |
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | SMITH KLINE BEECHAM CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2240178-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-10-20 | — | — | EP | disclosed |
| CN-101484164-A | Therapeutic use of 2-benzoyl-imidazopyridines | SANOFI AVENTIS (FR) | 2009-07-15 | — | — | CN | disclosed |
| WO-2009086044-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITH KLINE BEECHAM CORPORATION (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090143421-A1 | USE OF 2-BENZOYL-IMIDAZOPYRIDINES IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-06-04 | — | — | US | disclosed |
| EP-2040705-A2 | USE OF 2-BENZOYL-IMIDAZOPYRIDINES IN THERAPEUTICS | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008003855-A2 | USE OF 2-BENZOYL-IMIDAZOPYRIDINES IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298324-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | NOS3 295/4885NOS1 256/4885NOS2 136/4885 |
| US-20240199611-A1 | ANTIBACTERIAL COMPOUNDS | FDPS, MT-ND4, NDUFS3 | NOS3 1441/4885NOS1 1335/4885NOS2 1396/4885 |
| US-11731960-B2 | Biheterocyclic compound | NR4A3, NGF, OGFR | NOS3 386/4885NOS1 685/4885NOS2 870/4885 |
| US-20240180886-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | PTPN2, PTPN22, PTPN1 | NOS3 4303/4885NOS1 3998/4885NOS2 3281/4885 |
| US-20090143421-A1 | USE OF 2-BENZOYL-IMIDAZOPYRIDINES IN THERAPEUTICS | NCOR1, NR4A3, NR4A2 | NOS3 543/4885NOS1 831/4885NOS2 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.